Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMX-2043 for Periprocedural Injury Protection in CARIN
NCT02103959Phase 2Completed
- Sponsor
- Ischemix, Inc.
- Start
- Jun 2014
- Primary completion
- Sep 2015
- Modality
- Classical Binding Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of CMX-2043 in acute kidney injury (AKI) and cardiac injury (4 arms), sponsored by Ischemix, Inc. Primary endpoint: Prevention of acute kidney injury at 3 days. Started Jun 2014; status: completed.
02
Drugs
CMX-2043
03
Conditions
acute kidney injury (AKI)cardiac injury
Beyond the preview
Go deeper on NCT02103959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02103959.